TLR3 and melanoma: A recent study has demonstrated that human melanoma cells express TLR3, which in combination with TLR3 agonists, results in tumor cell death via caspase activation when cells are pretreated with cycloheximide or IFN-α (38), suggesting that TLR3 agonists may be multifunctional adjuvants offering more clinical treatment options.